Bristol’s Phase III Opdivo Data Clarify PD-1’s Place In Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
In the first randomized Phase III results for a PD-1 inhibitor to be presented at a major medical meeting, Bristol reports a 32% response rate for nivolumab compared to 11% for investigator’s choice of therapy in relapsed melanoma. Bristol immunotherapy exec Michael Giordano says the jury’s still out on PD-L1 as a predictive biomarker.
You may also be interested in...
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.